Diogo Boreski

Mr. Diogo Boreski

Drugs and Medicines Department, School of Pharmaceutical Sciences, University of São Paulo State (UNESP), Araraquara, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
DJDaniela Hartmann Jornada
Daniela Hartmann Jornada
Diogo BoreskiDiogo Boreski
Diogo Boreski
DCDiego Eidy Chiba
Diego Eidy Chiba
DLDenise Ligeiro
Denise Ligeiro
MLMarcus Alexandre Mendes Luz
Marcus Alexandre Mendes Luz
CCChung Man Chin
Chung Man Chin
Colorectal cancer (CRC) is one of the top 10 most common cancers worldwide and caused approximately 10 million deaths in 2022. CRC mortality has increased by 10% since 2020 and 52.000 deaths will occur in 2024, highlighting the limitations of current treatments due to ineffectiveness, toxicity, or non-adherence. The widely used chemotherapeutic agent, 5-fluorouracil (5-FU), is associated with several adverse effects, including renal, cardiac, and hepatic toxicity; mucositis; and resistance. Taurine (TAU), an essential β-amino acid with potent antioxidant, antimutagenic, and anti-inflammatory properties, has demonstrated protective effects against tissue toxicity from chemotherapeutic agents like doxorubicin and cisplatin. Taurine deficiency is linked to aging and cancers such as breast and colon cancer. This study hypothesized that TAU may mitigate the adverse effects of 5-fluorouracil (5-FU). Carcinogenesis was chemically induced in rats using 1,2-dimethylhydrazine (DMH). Following five months of cancer progression, taurine (100 mg/kg) was administered orally for 8 days, and colon tissues were analyzed. The results showed 80% of adenocarcinoma (AC) in DMH-induced control animals. Notably, the efficacy of 5-FU showed 70% AC and TAU 50% while, in the 5-FU + TAU group, no adenocarcinoma was observed. No differences were observed in the inflammatory infiltrate or the expression of genes such as K-ras, p53, and Ki-67 among the cancer-induced groups whereas APC/β-catenin expression was increased in the 5FU + TAU-treated group. The mitotic index and dysplasia were increased in the induced 5-FU group and when associated with TAU, the levels returned to normal. These data suggest that 5-FU exhibits a synergic anticancer effect when combined with taurine.

4 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Diogo BoreskiDiogo Boreski
Diogo Boreski
VSValentine Fabienne Schmid
Valentine Fabienne Schmid
PBPriscila Longhin Bosquesi
Priscila Longhin Bosquesi
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
CSCauê Benito Scarim
Cauê Benito Scarim
CCChung Man Chin
Chung Man Chin
The development of new drugs is a lengthy and complex process regarding its conception and ideation, passing through in silico studies, synthesis, in vivo studies, clinical trials, approval, and commercialization, with an exceptionally low success rate. The lack of efficacy, safety, and suboptimal pharmacokinetic parameters are commonly identified as significant challenges in the discovery of new drugs. To help address these challenges, various approaches have been explored in medicinal chemistry, including the use of prodrug strategies. As a well-established approach, prodrug design remains the best option for improving physicochemical properties, reducing toxicity, and increasing selectivity, all while minimizing costs and saving on biological studies. This review article aims to analyze the current advances using the prodrug approach that has allowed the advance of drug candidates to clinical trials in the last 10 years. The approaches presented here aim to inspire further molecular optimization processes and highlight the potential of this strategy to facilitate the advancement of new compounds to clinical study phases.

Verified
Journal Article
Open access
PDF file
MVMatheus Henrique Vieira
Matheus Henrique Vieira
Diogo BoreskiDiogo Boreski
Diogo Boreski
BMBibiana Matte
Bibiana Matte
Jean Lucas De Oliveira AriasJean Lucas De Oliveira Arias
Jean Lucas De Oliveira Arias
CJCelso Martins Júnior
Celso Martins Júnior
CCChung Man Chin
Chung Man Chin
Ozonized vegetable oils are gaining attention for their antimicrobial and therapeutic potential, yet the lack of standardized ozonation protocols and incomplete characterization of their chemical profiles hinder clinical translation. In this study, we standardized the ozonation process of sunflower oil and investigated the chemical evolution and antimicrobial efficacy of the resulting products. Ozonation proceeded through a classical three-step mechanism involving the formation of primary ozonides, their decomposition into carbonyl compounds and carbonyl oxides, and subsequent recombination into stable secondary ozonides capable of sustained ozone release with reduced toxicity. Time-course analysis at 100, 240, and 480 min revealed key reaction products, including the appearance of azelaic acid after 240 min, progressive depletion of linoleic acid, and the emergence of 2,5-furandione exclusively after 480 min—indicative of advanced oxidative processes. The formation of hydroperoxides and their secondary degradation into ketones, acids, and epoxides was also observed, with implications for both biological activity and sensory properties. Importantly, the ozonized oil demonstrated potent antimicrobial activity against Staphylococcus aureus, Escherichia coli, Salmonella choleraesuis, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. These findings provide a comprehensive chemical and functional characterization of ozonized sunflower oil and support its development as a standardized antimicrobial agent for therapeutic use.

15 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
PGPietra Santos Goularte
Pietra Santos Goularte
CICarlos Imperador
Carlos Imperador
FPFelipe Hassan Piedade
Felipe Hassan Piedade
AGAmanda Nascimento Guerin
Amanda Nascimento Guerin
KMKarina de Toledo Martins
Karina de Toledo Martins
CCChung Man Chin
Chung Man Chin
Pre-eclampsia (PE) affects about 5% of all pregnancies worldwide and is one of the leading causes of maternal and fetal morbidity and mortality. Some reports suggest that micronutrients may influence this condition, but there is no existing report analyzing data on copper (Cu), selenium (Se), and zinc (Zn) regarding quality and bias. Accurate information is crucial to support governmental healthcare actions, especially in developing countries such as Brazil. This study aims to investigate whether alterations in Zn, Cu, and Se levels in pregnant women contribute to the development of PE. We conducted the study following PRISMA guidelines and registered it on PROSPERO (CRD42022302298). We searched LILACS, PubMed/MEDLINE, EMBASE, and the Cochrane Library databases from January 2000 to January 2024. Of 1202 reports, 42 manuscripts were suitable for analysis (contained one or more micronutrients). A total of 76 individual analyses (by nutrient) were performed using Joanna Briggs Critical Appraisal and Cochrane Risk of Bias Tools. The analyses classified 69 reports as fair/low-quality with bias. Due to this, a meta-analysis was not conducted, as the results would not have accurately reflected reality. Of the high-quality reports, five on Cu showed conflicting results, while two studies on Zn found no differences in the level of this micronutrient between normal and PE pregnancies. No high-quality studies were identified for Se. The results highlight the need for robust guidelines for research involving micronutrients and PE to address this question effectively.

20 June 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
PRPatricia Rodella
Patricia Rodella
Diogo BoreskiDiogo Boreski
Diogo Boreski
MLMarcus Alexandre Mendes Luz
Marcus Alexandre Mendes Luz
EGEdmo Atique Gabriel
Edmo Atique Gabriel
LTLuiz Fernando Takase
Luiz Fernando Takase
CCChung Man Chin
Chung Man Chin
Taurine (2-aminoethanesulfonic acid) is a non-protein β-amino acid essential for cellular homeostasis, with antioxidant, anti-inflammatory, and cytoprotective properties that are crucial for life maintenance. This study aimed to evaluate the effects of taurine administration on hippocampal neurogenesis, neuronal preservation, or reverse damage in rats exposed to forced ethanol consumption in an animal model. Wistar rats were treated with ethanol (EtOH) for a 28-day period (5% in the 1st week, 10% in the 2nd week, and 20% in the 3rd and 4th weeks). Two taurine treatment protocols (300 mg/kg i.p.) were implemented: one during ethanol consumption to analyze neuroprotection, and another after ethanol consumption to assess the reversal of ethanol-induced damage. Overall, the results demonstrated that taurine treatment was effective in protecting against deficits induced by ethanol consumption in the dentate gyrus. The EtOH+TAU group showed a significant increase in cell proliferation (145.8%) and cell survival (54.0%) compared to the EtOH+Sal group. The results also indicated similar effects regarding the reversal of ethanol-induced damage 28 days after the cessation of ethanol consumption. The EtOH+TAU group exhibited a significant increase (41.3%) in the number of DCX-immunoreactive cells compared to the EtOH+Sal group. However, this amino acid did not induce neurogenesis in the tissues of healthy rats, implying that its activity may be contingent upon post-injury stimuli.

21 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Diogo BoreskiDiogo Boreski
Diogo Boreski
VSValentine Fabienne Schmid
Valentine Fabienne Schmid
PBPriscila Longhin Bosquesi
Priscila Longhin Bosquesi
Jean Leandro Dos SantosJean Leandro Dos Santos
Jean Leandro Dos Santos
CSCauê Benito Scarim
Cauê Benito Scarim
CCChung Man Chin
Chung Man Chin
The development of new drugs is a lengthy and complex process regarding its conception and ideation, passing through in silico studies, synthesis, in vivo studies, clinical trials, approval and commercialization, with an exceptionally low success rate. The lack of efficacy, safety, and suboptimal pharmacokinetic parameters are commonly identified as significant challenges in the discovery of new drugs. To help address these challenges, various approaches have been explored in Medicinal Chemistry, including the use of prodrug strategies. As a well-established approach, prodrug design remains the best option for improving physicochemical properties, reducing toxicity, and increasing selectivity, all while minimizing costs and saving on biological studies. This review article aims to analyze the current advances using prodrug approach that allows the advance of drug candidates to clinical trials in the last 10 years. The approaches presented here aim to inspire further molecular optimization processes and highlight the potential of this strategy to facilitate the advancement of new compounds to clinical study phases.